Medicaid Pays Millions in Excess Costs Due to Delayed Generic Drug Entry
Among the 69 brand-name drugs that were expected to lose market exclusivity between 2010 and 2015, only 38 products saw the launch of generic versions either before or within one quarter of the expected date, according to a recent study published in Health Affairs. For the 31 drugs whose generic entry was delayed by more than one quarter or did not occur, Medicaid incurred additional associated costs of $760.7 million between 2010 and 2016.
© 2023 MMIT